-
公开(公告)号：US11732266B2
公开(公告)日：2023-08-22
申请号：US17080771
申请日：2020-10-26
Applicant: AMGEN INC.
Inventor： Michael Ollmann , Yang Li , Jun Zhang , Oliver Homann , Leslie P. Miranda , Justin K. Murray , Bin Wu , Oh Kyu Yoon , John Gordon Allen , Chawita Netirojjanakul , Yuan Cheng
IPC: C12N15/113 , A61P9/10 , A61P3/06 , C07K16/28
CPC classification number: C12N15/1138 , A61P3/06 , A61P9/10 , C07K16/2851 , C07K2317/526 , C12N2310/14 , C12N2310/315 , C12N2310/317 , C12N2310/321 , C12N2310/332 , C12N2310/351 , C12N2310/3513 , C12N2310/321 , C12N2310/3521 , C12N2310/322 , C12N2310/3533 , C12N2310/322 , C12N2310/3531
Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
-
公开(公告)号：US20210163601A1
公开(公告)日：2021-06-03
申请号：US16987237
申请日：2020-08-06
Applicant: Amgen Inc.
Inventor： Paul Nioi , Peter Coward , Christopher Murawsky , Derek E. Piper , Fernando Garces , Jun Zhang , Yang Li , Brian Mingtung Chan
IPC: C07K16/28 , A61P9/10 , A61P9/04 , C12N15/113 , C07H21/02 , A61P3/06 , A61K39/395 , A61K45/06
Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
-
公开(公告)号：US20190248902A1
公开(公告)日：2019-08-15
申请号：US16230356
申请日：2018-12-21
Applicant: Amgen Inc.
Inventor： Paul Nioi , Peter Coward , Christopher Murawsky , Derek E. Piper , Fernando Garces , Jun Zhang , Yang Li , Brian Mingtung Chan
IPC: C07K16/28 , C07H21/02 , A61K39/395 , A61P9/10 , A61P9/04 , A61K45/06 , C12N15/113
CPC classification number: C07K16/2851 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61P9/04 , A61P9/10 , C07H21/02 , C07K14/705 , C07K16/28 , C07K2317/30 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N15/1138
Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
-
公开(公告)号：US11918650B2
公开(公告)日：2024-03-05
申请号：US15972489
申请日：2018-05-07
Applicant: AMGEN INC.
Inventor： Jeff Abel , Lingwen Cui , Devrishi Goswami , Joon Huh , Bharadwaj Jagannathan , Sekhar Kanapuram , Arnold McAuley , Michael Schneider , Ananthakrishnan G. Sethuraman , Michael Treuheit , Jun Zhang
IPC: A61K39/395 , A61K9/00 , A61K9/08 , A61K9/19 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/24 , A61K47/26 , C07K16/28 , C07K16/46 , A61J1/05 , A61J1/10 , A61K39/00
CPC classification number: A61K39/39591 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K39/3955 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/183 , A61K47/24 , A61K47/26 , C07K16/2803 , C07K16/2809 , C07K16/2863 , C07K16/468 , A61J1/05 , A61J1/10 , A61K2039/54 , A61K2039/545 , A61K2039/627 , C07K2317/24 , C07K2317/31 , C07K2317/41 , C07K2317/569
Abstract: The present invention provides an improved pharmaceutical composition for storage and administration comprising (a) a bispecific antibody construct comprising a first domain binding to a target cell surface antigen and a second domain binding to a second antigen, wherein the bispecific antibody construct is present at a concentration in the range from about 0.5 μg/ml to 20 mg/ml, (b) a preservative at a concentration effective to inhibit the growth of microbes, and (c) a diluent wherein bispecific antibody construct is stable and recoverable.
-
Patent Agency Ranking
公开(公告)号：US20240208680A1
公开(公告)日：2024-06-27
申请号：US18288549
申请日：2022-05-19
Applicant: AMGEN INC.
Inventor： Devrishi Goswami , Jun Zhang , Deirdre Piedmonte , Vikashni Padmakumar , David Le , Maria Raquel Santos , Wei Qi
Abstract: A method of filing a vial. The method includes providing a pump corresponding to a vial and setting a drip retraction parameter for the pump to any value equal to or less than 20 degrees. The method also includes setting a no adjustment limit for a fill weight of the vial to T1, with T1 being at or in a range of about 2% more or less than a fill weight of a target fill weight T0, wherein a process performance index Cpk (Cpk) for the vial throughout a fil cycle exceeds a minimum value.
-
公开(公告)号：US10358497B2
公开(公告)日：2019-07-23
申请号：US15279162
申请日：2016-09-28
Applicant: Amgen Inc
IPC: C12N15/113 , C07H21/02 , A61P9/04 , A61P9/10 , C07K16/28 , A61K39/395 , A61K45/06 , C07K14/705 , A61K39/00
Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
-
7.发明申请公开(公告)号：US20190151448A1
公开(公告)日：2019-05-23
申请号：US15972489
申请日：2018-05-07
Applicant: AMGEN INC.
Inventor： Jeff Abel , Lingwen Cui , Devrishi Goswami , Joon Huh , Bharadwaj Jagannathan , Sekhar Kanapuram , Arnold McAuley , Michael Schneider , Ananthakrishnan G. Sethuraman , Michael Treuheit , Jun Zhang
IPC: A61K39/395 , C07K16/28 , A61K47/10 , A61K47/14 , A61K47/24 , A61K47/12 , A61K47/26 , A61K47/18 , C07K16/46
Abstract: The present invention provides an improved pharmaceutical composition for storage and administration comprising (a) a bispecific antibody construct comprising a first domain binding to a target cell surface antigen and a second domain binding to a second antigen, wherein the bispecific antibody construct is present at a concentration in the range from about 0.5 μg/ml to 20 mg/ml, (b) a preservative at a concentration effective to inhibit the growth of microbes, and (c) a diluent wherein bispecific antibody construct is stable and recoverable.
-
公开(公告)号：US20250051457A1
公开(公告)日：2025-02-13
申请号：US18770259
申请日：2024-07-11
Applicant: Amgen Inc.
Inventor： Paul Nioi , Peter Coward , Christopher Murawsky , Derek E. Piper , Fernando Garces , Jun Zhang , Yang Li , Brian Mingtung Chan
IPC: C07K16/28 , A61K39/00 , A61K39/395 , A61K45/06 , A61P3/06 , A61P9/04 , A61P9/10 , C07H21/02 , C07K14/705 , C12N15/113
Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
-
公开(公告)号：US20170088620A1
公开(公告)日：2017-03-30
申请号：US15279162
申请日：2016-09-28
Applicant: Amgen Inc.
Inventor： Paul Nioi , Peter Coward , Christopher Murawsky , Derek E. Piper , Fernando Garces , Jun Zhang , Yang Li , Brian Mintung Chang
IPC: C07K16/28 , A61K45/06 , A61K39/395
CPC classification number: C07K16/2851 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61P9/04 , A61P9/10 , C07H21/02 , C07K14/705 , C07K16/28 , C07K2317/30 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N15/1138
Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.061 seconds)
